Skip to main content

Table 1 Patient Demographics and Baseline Characteristics (Safety Population)

From: Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator

Baseline characteristic Total population (N = 16)
Age, years 39.0 (11.8)
Male, n (%) 16 (100)
Race, n (%)
 Asian 1 (6.3)
 Black or African American 1 (6.3)
 White 14 (87.5)
Weight, kg 82.5 (15.6)
Height, cm 174.9 (7.9)
Body mass index, kg/m2 26.8 (3.5)
Smoking status, n (%)
 Former 1 (6.3)
 Never 15 (93.8)
Asthma severity per GINA 2006 stages, n (%)
 Category Ia 8 (50.0)
 Category IIb 8 (50.0)
Duration of asthma, years 25.9 (11.5)
Prebronchodilator % predicted FEV1 80.8 (9.3)
Bronchial reversibility, % 20.2 (7.9)
Prior medicationc for asthma, n (%) 1 (6.3)
  1. FEV1 forced expiratory volume in 1 s, GINA Global Initiative for Asthma
  2. Data are mean (standard deviation) unless otherwise specified
  3. aFEV1 ≥ 80% of predicted value (mild persistent)
  4. bFEV1 ≥ 60% of predicted value and < 80% of predicted value
  5. cWithin 15 days prior to providing informed consent until the first administration of study medication